This Article contains errors in the Acknowledgements section.
“The authors acknowledge funding support from the National Health and Medical Council of Australia (1004926).”
should read:
“The authors acknowledge funding support from the National Health and Medical Research Council of Australia (1004926) and Diabetes Australia.”
Additional information
The online version of the original article can be found at 10.1038/srep26428
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Gallo, L., Ward, M., Fotheringham, A. et al. Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep 6, 28124 (2016). https://doi.org/10.1038/srep28124
Published:
DOI: https://doi.org/10.1038/srep28124
